Kathy Boltz, PhD | Authors


Nivolumab Combinations Feasible for Newly Diagnosed GBM

November 20, 2016

The PD-1 inhibitor nivolumab was successfully combined with radiotherapy alone or concurrently with temozolomide for patients with newly-diagnosed glioblastoma multiforme in cohorts 1c and 1d from the phase I CheckMate-143 study.

Pembrolizumab Active, Tolerable for Recurrent Glioblastoma

November 19, 2016

Treatment with the PD-1 inhibitor elicited a durable clinical benefit rate of 28% along with a manageable safety profile for patients with recurrent glioblastoma multiforme that expressed PD-L1 on ≥1% of cells.

Novel Gene Therapy Effective for High-Grade Gliomas

November 19, 2016

Treatment with the novel regimen of Toca 511 and Toca FC demonstrated a median overall survival of 13.6 months for patients with high-grade gliomas, representing a marked improvement over historical median survivals of 7.2 to 9.2 months.